Background {#Sec1}
==========

Terminal deletions of the long arm of chromosome 11 have been numerously described, and they are associated with Jacobsen syndrome (OMIM 147791) and characterized by thrombocytopenia, mental retardation, short stature, congenital heart defect, and characteristic facial dysmorphism \[[@CR1], [@CR2]\]. On the contrary, interstitial deletions of the long arm of chromosome 11 are less common and often not fine-mapped, due to the similarity between band patterns (11q14 and 11q22) when conventional karyotype is performed \[[@CR3], [@CR4]\]. So far, approximately 30 cases of 11q interstitial deletions have been reported \[[@CR3]--[@CR24]\]. Nevertheless, due to high variability of size and position of the deleted regions, phenotype-genotype correlations have been hard to evaluate due to the wide range of phenotypic features, ranging from normal to severe conditions including developmental delay/mental retardation, facial dysmorphisms and other medical implications. Moreover, before the introduction of molecular cytogenetic approaches, the resolution efficiency provided by conventional karyotype analysis jointly with the symmetric 11q banding pattern \[[@CR3], [@CR4]\], limited the accuracy of identification of breakpoints and precise deleted genomic regions.

Case presentation {#Sec2}
-----------------

The patient, a 13-year old boy, was the first and only child of unrelated healthy Caucasian parents. He was born by cesarean section after a full term pregnancy. Birth weight was 2,800 g (10^th^ percentile), length 50 cm (50^th^ percentile) and head circumference (HC) 35.5 cm (50^th^ percentile). Neonatal and infancy periods were uneventful; nevertheless his motor development was delayed as he did not sit independently until the age of 15 months or walk unaided until the age of 22 months.

At the age of 5, language delay was observed and laboratory investigation was performed, including audiogram, biochemical and thyroid tests, which proved normal. He received speech therapy for a two-year period and his language difficulties resolved. He attended mainstream primary school with extra educational support and finished this level at the age of 12 years. At the age of 13 years he was referred for full developmental assessment because he was experiencing severe learning difficulties in secondary school. Upon physical examination, he was characterized as quite a sociable child, with mild dysmorphic facial features such as almond shaped eyes, hypertelorism, anteverted nostrils, and gothic palate. His weight at the time was 49 kg (40^th^ percentile), height 160 cm (60^th^ percentile) and HC 54 cm (25^th^ percentile). Upon neurological examination, he showed mild motor delay with severe clumsiness but without focal neurological signs. Ophthalmologic examination was normal. Heart auscultation revealed a mild systolic murmur.

Upon developmental evaluation, he was found to function at the mental level of a 10-year old. His cognitive abilities, according to the Wechsler Intelligence Scale for Children test (WISC III), were assessed as borderline, as his full-scale score was 75 with verbal score 75 and performance score 80.

Extensive laboratory investigation followed, including brain magnetic resonance imaging (MRI), electroencephalogram, kidney-liver- spleen ultrasound, bone age, biochemical tests, blood and urine amino acids, organic acids, very low fatty acids, thyroid function, ACTH, FSH, LH, DHEA-S, prolactin, estradiol e2, progesterone, testosterone, 17a-OH progesterone and IGF-1, all proved normal. Heart ultrasound showed mild mitral valve prolapsed.

Material and methods {#Sec3}
====================

Metaphase chromosomes were obtained from phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes and high resolution (thymidine treatment) G-banding karyotype analysis was performed, using standard procedures. The conventional cytogenetic analysis revealed a de novo interstitial deletion on the long arm of chromosome 11, involving 11q14 and 11q22 breakpoints (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1G-banding karyotype of the patient. It is illustrated the interstitial deletion on the long arm of chromosome 11

To further investigate the specific finding, array-CGH was performed by hybridizing the sample against a male human reference commercial DNA sample (Promega biotech) using an array-CGH platform that includes 60000 oligonucleotides distributed across the entire genome (Agilent Technologies). The statistical test used as parameter to estimate the number of copies was ADAM-2 (provided by the DNA analytics software, Agilent Techn) with a window of 0.5 Mb, A=6. Only those copy number changes that affected at least 5 consecutive probes with identically oriented change were considered as Copy Number Variations (CNV). As a consequence, for the majority of the genome, the average genomic power of resolution of this analysis was 200 kilobases.

Array-CGH analyses detected an interstitial deletion spanning region 11q14.2-11q22.1, genomic coordinates chr11: 85,702,633-97,854,695 (Genomic coordinates are listed according to genomic build GRCh37/hg19). No additional pathogenetic Copy Number Variations (CNVs) were detected and thus the molecular karyotype was: arr 11q14.2q22.1 (85702633--97854695)x1 (Fig. [2](#Fig2){ref-type="fig"}). The specific deletion contains approximately 12,15 Mb of genomic material and includes 30 OMIM listed genes (Table [1](#Tab1){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Ideogram of the deleted region as it is detected using array CGH. The interstitial deletion is at 11q14.2-11q22.1Table 1OMIM listed genes included in the 11q14.2-11q22.1 regionGeneOMIMStartEndCytogenetic regionDescriptionProtein functionPICALM603025856684855875010811q14.2Phosphatidylinositol binding clathrin assembly proteinInvolved in cellular trafficking, regulation of endocytosis, and clathrin-mediated vesicle formationEED605984859558158598978111q14.2Embryonic ectoderm developmentMediates repression of gene activity through histone deacetylation*ME3*604626861521508638367811q14.2Malic enzyme 3, NADP(+)-dependent, mitochrondrialCatalyzes the oxidative decarboxylation of malate to pyruvate using either NAD+ or NADP+ as a cofactor*FZD4*604579866567218666643311q14.2Frizzled homolog 4 (Drosophila)Receptor for Wnt proteins*RAB38*606281878464318790859911q14.2RAB38, member RAS oncogene familyMay be involved in melanosomal transport and docking*CTSC*602365880267608807094111q14.2Cathepsin CLysosomal protease capable if removing dipeptides from the amino terminus of protein substrates*GRM5*604102882377448879681611q14.2Glutamate receptor, metabotropic 5Transduce signals from extra cellular transmitters to the inside of the cell by activating G proteinsTYR606933889110408902892711q14.3Tyrosinase (oculocutaneous albinismIA)Conversion of tyrosine to melanin*NOX4*605261890575218923136311q14.3NAPDH pxidase 4may function as catalytic component of an endothelial NAPDH oxidase/may fulfill the function of oxygen sensor in the kidney*FOLH1B*609020893924658943188611q14.3Folate hydrolase 1Bhydrolyzes beta-citrylglutamate/ found in the CNS during pre-perinatal periods of development in the testis in adult males*TRIM49*606124895308238954174311q14.3Tripartite motif containing 49Protein-protein interaction. Expressed mostly in testis*NAAIAD2*611636898678188992577911q14.3N-acetylated alpha-linked acidic dipeptidase 2NAALADase activity. Inactivate the peptide neurotransmitter N-acetylaspartylglutamate*CHORDC1*604353899335978995653211q14.3Cysteine and histidine-rich domain (CHORD) containing 1Function of the wildtype gene in nematode development*FAT3*612483920852629262963611q14.3FAT tumor suppressor homolog 3 (Drosophila)Cell adhesionMTNR1B600804927027899271594811q14.3Melatonun receptor 1BReceptor for malatonin, proton-coupled receptors*C11orf75*609477932116389327654611q21Chromosome 1 open reading frame 75TAF1D612823934690959347470311q21TATA box binding proteinComponent of the transcription factor SL1/TIF-IB complex. Downregulation induced apoptotic cell deathMED17603810935174059354649611q21Mediator complex subunit 17Mammalian mediator of transcriptional regulationPANX1608420938620949391513911q21PannexinStructural component of the gap junctions and the hemichannels*GPR83*605569941104779413458511q21G protein-coupled receptor 83Orphan receptorMRE11A600814941504669422704011q21MRE11 meiotic recombination 11 homolog ADouble-strand break repair, DNA recombination, maintenance of telomere integrity and meiosisFUT4104230942770179428306411q21Fucosyltransferase 4 (alpha (1,3)) myeloid-specificBiosynthesis of lewis antigenePIWIL4610315943004749435458711q21Piwi-like 4 (Drosophila)Development and maintenance of germline stem cells*KDM4D*609766947068459473267811q21Lysine (K)-specific demethylase 4DHistone codingSRSF8603229948000569480438811q21Serine/arginine-rich splicing factor 8Involved in pre-mrna alternative splicingSESN3607768949061139496424611q21Sestrin 3Normal regulation of blood glucose, insulin resistanceCEP57607951955236429556585411q21Centrosomal protein 57 kdaRequired for microtubule attachment to centrosomes*MTMR2*603557955660449565737111q21Myotubularin related protein 2Tyrosine phosphataseMAML2607537957114409607634411q21Mastermind-like 2 (Drosphila)Transcriptional coactivator for NOTCH proteinsJRKL603211961231589612672711q21Jerky homolog-like (mouse)Not yet defined, probably nuclear regulatory proteinFig. 3The 11q14.2 -- 11q22.1 region is haploinsufficient to the current patient. The red box shows the region which is deleted. Below the chromosome ideogram are the transcripts of genes which are in the 11q14.2-11q22.1 region (<http://genome.ucsc.edu/>)

Discussion {#Sec4}
==========

Here we report a patient with a *de novo* 12.15 Mb interstitial deletion of chromosome 11 long arm, spanning from nt85702633 to nt97854695, exhibiting developmental delay, borderline mental retardation, severe speech delay, and some dysmorphic features. The genotype of the patient was compared to 19 previously described patients carrying overlapping interstitial deletions of chromosome 11 long arm (Fig. [4](#Fig4){ref-type="fig"}). Cases with uncertain or not accurately defined breakpoints were not considered \[[@CR4], [@CR5], [@CR13], [@CR24]\].Fig. 4Cases with overlapping interstitial deletions of chromosome 11 long arm. The blue lines show the deletion of each patient, and the pink region illustrates the overlapping region of the present case with the other cases

Regarding these 19 cases, only six studies \[[@CR9]--[@CR12], [@CR25], [@CR26]\] were conducted using molecular cytogenetic techniques, such as a-CGH analysis with BAC clones or high-density oligonucleotide probes. In the remaining cases, conventional karyotype analysis and/or fluorescence in situ hybridization analysis was performed in order to define the position and size of the deletions. Table [2](#Tab2){ref-type="table"} summarizes the genotypes and phenotypic features of the present case and of the 19 cases with overlapping interstitial deletions of chromosome 11 long arm.Table 2Genotypes and phenotypic features of the present case and of the 19 cases with overlapping interstitial deletions of chromosome 11 long arm

As listed in Table [2](#Tab2){ref-type="table"}, most of the patients with an overlapping deletion of this region had mild to severe developmental delay, short stature/growth delay, high narrow palate or cleft palate/lip with or without migrognathia, and minor digital anomalies. Other clinical features include skeletal anomalies, brain anomalies, cranial dysmorphisms (microcephaly, trigonocephaly), retinal dysgenesis/exudative vitroretinopathy (EVR), genital anomalies, kidney anomalies and heart defects \[[@CR7], [@CR10], [@CR11], [@CR13], [@CR19]\]. Regarding the present case with the exception of hypertelorism, and gothic palate our patient had none of these features.

However it is obvious (Table [2](#Tab2){ref-type="table"}) that there are two cases, both without phenotypic abnormalities or developmental delay, which carry similar deletion with the present case. Li et al. \[[@CR8]\] described five cases of 11q14.3-q21 deletion transmitted through three-generation kindred. The proband showed short stature and mild attention deficit disorder that required teaching assistant, all other family members were healthy despite carrying the deletion. The deleted region was mapped by FISH with overlapping BAC clones. The entire contig spans 3,6 Mb, and the breakpoints are within clones RP11-792 M23 and RP11-573 M3. In this region there are few genes and only two (MTNBR1 and NAALAD) are single copy genes. Other genes in this region have at least one copy present elsewhere in the genome that might compensate for the deleted copies of these genes.

Goumy et al. \[[@CR6]\] described three cases of 11q14.3-q22.1 deletion transmitted in three-generation kindred. The proband, a normal girl without dysmorphic features, was tested during mother's pregnancy by genetic amniocentesis because of a positive Down syndrome maternal serum screening test at 15 weeks gestation. The deletion was identified in the mother, who had toe camptodactyly and ophthalmologic disorders, and in the phenotipically normal grandfather. The minimal deletion size, mapped by combining CGH analysis and FISH with BAC clones was 8.5 Mb from RP11-372E19 to RP11-775E2. This region contains almost 17 genes in common with those of our case. There might be other genes with similar functions located elsewhere in the genome. Another hypothesis that could explain the lack of phenotypic abnormalities was the haplosufficiency: the adequate functioning of the genes of this region in single copy. Both paternal and maternal origin in the transmission of the deletion, excluded genetic imprinting as explanation of the normal phenotype.

Present case differs from these cases for the presence of 11q14.2 cytogenetic region, exactly from nt 85,668,485 to the first absent BAC clone in case described by Li et al. \[[@CR8]\] approximately near the nt 89,255,000. In this region there are genes that should be responsible for the phenotype of this patient. Among the genes contained in the region, GRM5 (Glutamate receptor, metabotropic 5 gene OMIM604102) is particularly interesting. Metabotropic glutamate receptors (mGluRs) are G protein-coupled receptors (GPCRs) which transduce signals from the extracellular matrix to the cytoplasm by activating G proteins*.* One prominent action of group I mGluRs is to protect neurons from apoptotic death \[[@CR27]\].

GRM5 plays an important role in modulating neural activity and plasticity \[[@CR28], [@CR29]\]. Its signaling is required for different forms of adaptive learning because impaired receptor function results in inappropriate retention of aversive memories, which seems to be related with impaired long-term potentiation in CA1 region and dentate gyrus of the hippocampus \[[@CR30], [@CR31]\]. Several neurological and neurodevelopmental disorders are associated with an abnormal function of this gene such as Fragile X syndrome, Schizophrenia anxiety, depression, and addiction \[[@CR32]--[@CR34]\]. All cases which overlaps our case, and in which the deletion includes this gene region, presents developmental delay.

There are four other cases in which developmental delay was present but the region containing this gene was not deleted \[[@CR16], [@CR19], [@CR20], [@CR25]\]. However, the region deleted in this four cases includes another Glutamate receptor family gene in 11q22.3 GRIA4 (Glutamate Receptor Ionotrophic Ampa 4) that mediates fast synaptic excitatory neurotransmission (OMIM 138246) and this gene is also implied in neurological disorders in mice \[[@CR35]\].

The patients who had normal development had no copy-number variations of both GRM5 and GRIA4 genes \[[@CR6], [@CR8], [@CR17]\]. Only in the case described by Sparkes et al. \[[@CR11]\], resulted a normal development despite the GRIA4 gene deletion. When the deletions included both genes, there was a more severe phenotype \[[@CR20], [@CR21]\]. We hypothesize that both these genes could be associated with developmental delay in 11q interstitial deletions.

The remaining features were impossible to be correlated with any genotype because the deletions in different cases seem to generate many different phenotypes. These chromosomal deletions generally involve a large number of genes, but most of these genes are not dosage sensitive and a single copy of the gene ensures its function. In this situation, when a clinical phenotype was observed, would always be appropriate to analyze the genes on the intact chromosome in order to find mutations. Another mechanism could be the presence of copies or similar genes located elsewhere in the genome that show a compensatory gene expression. Also a deletion within a region subject to genomic maternal or paternal imprinting might not cause pathological phenotype. Therefore further work should be done in animal model organisms in order to fully understand the function of these genes and the pathways that contribute to the phenotype.

Conclusion {#Sec5}
==========

On the basis of current literature we are not yet able to define a monosomy 11q phenotype. Many other studies and accurate molecular characterization are needed to understand the complex genetic and environmental relationship that underlie the phenotypic differences observed in similar cases of chromosomal rearrangements.

Consent {#Sec6}
=======

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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:   Array comparative genomic hybridization
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CNV

:   Copy number variation
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